A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Ofatumumab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 12 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2012 Planned number of patients changed from 112 to 162.